Bottom line
- For adult septic shock, SSC 2026 suggests IV corticosteroids (conditional, low certainty; as summarized by Kim 2026).
- Usual regimen: hydrocortisone 200 mg/day IV, as 50 mg every 6 hours or a continuous infusion. Duration and tapering are not settled.
- Fludrocortisone, if added: 50 mcg by mouth or gastric tube once daily for 7 days with hydrocortisone (Annane 2002, APROCCHSS). Reasonable; benefit not proven.
- SSC 2021 suggested starting at norepinephrine or epinephrine 0.25 mcg/kg/min or more, "at least 4 h after initiation"; SSC 2026 reportedly drops it (Kim 2026).
Introduction
- Scope: adults with septic shock. Not sepsis without shock: in HYPRESS, hydrocortisone did not reduce progression to septic shock (Keh 2016). Children are not covered; these doses do not apply to them.
- Sepsis (Sepsis-3): life-threatening organ dysfunction (SOFA increase of 2 points or more) caused by a dysregulated host response to infection.
- Septic shock (Sepsis-3): sepsis needing a vasopressor to keep MAP at 65 mm Hg or higher, with serum lactate above 2 mmol/L despite adequate volume.
- Sepsis is a clinical diagnosis; no single biomarker or test rules it in or out (SSC 2026). Collect blood cultures as soon as possible, ideally before antimicrobials. SSC 2026, as summarized by Kim 2026: antimicrobials immediately, ideally within 1 hour of recognition, for possible, probable or definite septic shock; at least 30 mL/kg IV crystalloid in the first 3 hours for sepsis-induced hypoperfusion or septic shock (suggestion, low certainty), from actual body weight, or adjusted or ideal body weight when BMI is above 30 kg/m2. Reassess often.
Pharmacology
Swipe sideways to see all columns.
| Hydrocortisone | Methylprednisolone | Fludrocortisone | |
|---|---|---|---|
| Adult dose in septic shock (HC and MP labels give no renal or hepatic adjustment) | 200 mg/day IV: 50 mg every 6 h or continuous infusion. Duration and tapering not settled | Not preferred in septic shock. Do not use high-dose, short-course regimens | If added: 50 mcg (0.05 mg) once daily for 7 days with hydrocortisone, the Annane 2002 and APROCCHSS regimen. Benefit of adding it not proven (COIITSS) |
| Administration | IV injection over 30 seconds (e.g., 100 mg) to 10 minutes (e.g., 500 mg or more). Continuous infusion: 200 mg over 24 h; reconstituted 100 mg vial added to 100 to 1,000 mL of a listed diluent | IV injection over several minutes, or IV infusion | By mouth or gastric tube. 0.1 mg scored tablets: 50 mcg is half a tablet. In septic shock, levels varied widely after an enteral dose, indicating differing absorption (Walsham 2024) |
| Adverse effects | Increased blood pressure, fluid retention, hyperglycemia, weight gain, increased appetite, altered behavior. Neuromuscular weakness (more in SSC 2021 meta-analysis and HYPRESS). Superinfection: more in CORTICUS; label warns of infection risk; Pirracchio 2023: no clear increase (low certainty) | Hypertension; fluid and sodium retention, potassium loss, hypokalemic alkalosis; decreased glucose tolerance; increased appetite; weight gain; muscle weakness, steroid myopathy; psychic disorders; decreased resistance to infection | Mostly mineralocorticoid: sodium and water retention, hypertension, edema, potassium loss |
| Monitoring | Glucose (more hyperglycemia with HC + FC, APROCCHSS); intensive insulin: no mortality benefit, more severe hypoglycemia (below 40 mg/dL) than conventional (COIITSS). Sodium, potassium; hypernatremia may be more frequent (Pirracchio 2023, low certainty). Signs of new infection. Muscle strength, especially with neuromuscular blockers | Glucose (hyperglycemia). Blood pressure, salt and water retention, potassium excretion. Signs of infection. Muscle strength, especially with neuromuscular blockers | Blood pressure and serum electrolytes, regularly. Serum potassium at frequent intervals with amphotericin B or potassium-depleting diuretics |
| Warnings | Adrenal suppression; immunosuppression (higher doses, longer therapy); psychiatric changes; live vaccines contraindicated with immunosuppressive doses. Caution in heart failure, hypertension, renal insufficiency (sodium retention, edema, potassium loss). Stronger effect in cirrhosis | Adrenal suppression. Rarely, toxic acute hepatitis with high-dose, cyclically pulsed IV methylprednisolone. Caution in systemic sclerosis (scleroderma renal crisis), heart failure, hypertension, renal insufficiency. Stronger effect in cirrhosis | Off-label in septic shock (label indications: Addison's disease, salt-losing adrenogenital syndrome); marked sodium retention, so label advises against other uses. Caution in hepatic dysfunction (stronger in cirrhosis), thyroid disease (stronger in hypothyroidism), renal insufficiency, hypertension, myasthenia gravis |
| Interactions: potassium, glucose, clotting | Potassium-depleting drugs (amphotericin B, diuretics): watch for hypokalemia. Insulin and other antidiabetics: doses may need adjustment. Warfarin: monitor coagulation indices frequently | Potassium-depleting drugs (amphotericin B, diuretics): watch for hypokalemia. Antidiabetics: doses may need adjustment. Warfarin: monitor coagulation indices frequently | Amphotericin B, potassium-depleting diuretics: enhanced hypokalemia. Digitalis: arrhythmias or toxicity with hypokalemia. Oral anticoagulants: decreased prothrombin time response. Antidiabetics, oral and insulin: diminished effect |
| Interactions: other | CYP3A4 inducers such as rifampin, phenytoin, carbamazepine: may need higher steroid dose. CYP3A4 inhibitors such as ketoconazole, macrolides: higher steroid levels. Neuromuscular blockers such as pancuronium: acute myopathy. DDAVP (desmopressin): risk of hyponatremia (not listed in the FDA label) | CYP3A4 inducers such as rifampin, phenytoin, carbamazepine: may need higher steroid dose. CYP3A4 inhibitors such as ketoconazole, macrolides: higher steroid levels. Neuromuscular blockers such as pancuronium: acute myopathy | Barbiturates, phenytoin, rifampin: faster clearance. Aspirin. Anabolic steroids: edema. Vaccines. Estrogen |
| Compatibility and storage | For infusion: D5W, or NS or D5NS if not sodium-restricted. Do not dilute or mix with other solutions. Use reconstituted or diluted solution within 12 h of preparation; refrigerated unused solution within 24 h. Infusion duration does not establish room-temperature use time | For infusion: D5W, NS or D5NS. Do not dilute or mix with other solutions. Incompatible: lactated Ringer's (not mentioned in the FDA label) | N/A (oral tablet) |
HC = hydrocortisone; MP = methylprednisolone; FC = fludrocortisone; NMA = network meta-analysis. Sources: FDA labels (references 22 to 24), the trials and guidelines in the tables, UpToDate and Micromedex (references 18, 19).
Key evidence
Swipe sideways to see all columns.
| Author, year | Design (n) | Intervention and comparison | Key findings |
|---|---|---|---|
| Walsham, 2024 | Phase II open-label RCT, stopped early (n=153) | HC alone vs HC + FC 50, 100 or 200 mcg daily; ventilated (invasive or non-invasive) | No difference in time to shock resolution (median 3 days in every arm). Excluded patients on long-term corticosteroids |
| Teja, 2024 | Bayesian NMA (17 RCTs, n=7,688) | HC + FC vs HC alone vs placebo | HC + FC lowest mortality (RR 0.85 vs placebo); HC alone RR 0.97, not significant. HC + FC vs HC alone RR 0.88 (95% CrI 0.74 to 1.03), mostly indirect evidence |
| Lai, 2024 | Bayesian NMA + target-trial emulation (n=95,841) | HC + FC vs HC alone vs placebo; 19 studies | HC + FC lowest short-term mortality vs placebo (OR 0.79; NNT 21, range 12 to 500); low certainty |
| Pirracchio, 2023 | Patient-level meta-analysis (17 trials, n=7,882) | HC vs placebo; 90-day mortality from 7 trials (n=5,929) | 90-day mortality not significantly lower (RR 0.93, 95% CI 0.82 to 1.04; moderate certainty): 0.86 (0.79 to 0.92) with FC, 0.96 (0.82 to 1.12) without. More vasopressor-free days (high certainty) |
| Annane, 2018 (APROCCHSS) | RCT (n=1,241) | HC 50 mg IV every 6 h + FC 50 mcg once daily by nasogastric tube, 7 days, vs placebo | Lower 90-day mortality (43.0% vs 49.1%; RR 0.88, 95% CI 0.78 to 0.99); more vasopressor-free and organ failure-free days; ventilator-free days similar; more hyperglycemia |
| Venkatesh, 2018 (ADRENAL) | RCT, ventilated patients (n=3,800) | HC 200 mg/day continuous infusion vs placebo, 7 days or until ICU discharge | No difference in 90-day mortality (27.9% vs 28.8%); faster shock resolution, shorter initial ventilation, fewer transfusions (37.0% vs 41.7%) |
| Gibbison, 2017 | Systematic review + NMA (22 studies) | Steroid molecule and regimen comparisons | No regimen clearly better for mortality; HC bolus or infusion more likely than methylprednisolone or placebo to reverse shock |
| Annane, 2010 (COIITSS) | 2x2 factorial RCT (n=509) | In HC-treated septic shock: + FC vs no FC, and intensive vs conventional insulin | Adding FC did not significantly lower in-hospital mortality (42.9% vs 45.8%); intensive insulin gave no mortality benefit and more severe hypoglycemia |
| Sprung, 2008 (CORTICUS) | RCT (n=499) | HC 50 mg IV every 6 h for 5 days, then a 6-day taper, vs placebo | No difference in 28-day mortality (34.3% vs 31.5%); shock reversed faster only among patients whose shock reversed; more superinfections |
| Annane, 2002 | RCT (n=300) | HC 50 mg IV every 6 h + FC 50 mcg PO daily, 7 days, vs placebo | Lower 28-day mortality in corticotropin nonresponders (53% vs 63%; HR 0.67, 95% CI 0.47 to 0.95); faster vasopressor withdrawal; similar adverse events |
Clinical conclusions
HC shortened time to shock resolution (ADRENAL, median 3 vs 4 days); HC + FC gave more vasopressor-free days (APROCCHSS, 17 vs 15 to day 28); CORTICUS: no better reversal overall.
Mortality is mixed: benefit with HC + FC in APROCCHSS and in Annane 2002 corticotropin nonresponders; none with HC alone (CORTICUS, ADRENAL).
Adding FC: no significant mortality benefit in COIITSS and no faster shock resolution in Walsham 2024. Teja 2024, Lai 2024 and Bosch 2023 favor it, mostly indirect or observational evidence.
Fludrocortisone retains sodium and water and increases potassium loss: caution in heart failure, hypertension and renal insufficiency; stronger effect in cirrhosis or hypothyroidism. Check blood pressure and serum electrolytes regularly.
Hydrocortisone is preferred over methylprednisolone (shock reversal, Gibbison 2017); head-to-head data are observational, with no significant mortality difference (Yu 2009; Xu 2025). Dexamethasone is not guideline-preferred.
SCCM 2024 recommends against high-dose, short-duration corticosteroid regimens in septic shock. Check your protocol for the start trigger your unit uses.
Educational summary for pharmacists. Not a substitute for clinical judgment or institutional protocol.
References
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287. PMID: 26903338.
- Prescott HC, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725-812. doi:10.1097/CCM.0000000000007075. PMID: 41869847. Also published in Intensive Care Med. 2026;52(5):863-936. doi:10.1007/s00134-026-08361-1. PMID: 41870560. Publisher correction to the Intensive Care Med version: Intensive Care Med. 2026;52(6):1411-1413. doi:10.1007/s00134-026-08410-9. PMID: 42084789.
- Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y. PMID: 34599691.
- Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024;52(5):e219-e233. doi:10.1097/CCM.0000000000006172. PMID: 38240492.
- Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862-871. doi:10.1001/jama.288.7.862. PMID: 12186604.
- Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124. doi:10.1056/NEJMoa071366. PMID: 18184957.
- Yu TJ, Liu YC, Yu CC, Tseng JC, Hua CC, Wu HP. Comparing hydrocortisone and methylprednisolone in patients with septic shock. Adv Ther. 2009;26(7):728-735. doi:10.1007/s12325-009-0043-4. PMID: 19629409.
- Annane D, Cariou A, Maxime V, et al; COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010;303(4):341-348. doi:10.1001/jama.2010.2. PMID: 20103758.
- Keh D, Trips E, Marx G, et al; SepNet Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA. 2016;316(17):1775-1785. doi:10.1001/jama.2016.14799. PMID: 27695824.
- Gibbison B, López-López JA, Higgins JP, et al. Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care. 2017;21(1):78. doi:10.1186/s13054-017-1659-4. PMID: 28351429.
- Venkatesh B, Finfer S, Cohen J, et al; ADRENAL Trial Investigators. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797-808. doi:10.1056/NEJMoa1705835. PMID: 29347874.
- Annane D, Renault A, Brun-Buisson C, et al; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809-818. doi:10.1056/NEJMoa1705716. PMID: 29490185.
- Bosch NA, Teja B, Law AC, Pang B, Jafarzadeh SR, Walkey AJ. Comparative effectiveness of fludrocortisone and hydrocortisone vs hydrocortisone alone among patients with septic shock. JAMA Intern Med. 2023;183(5):451-459. doi:10.1001/jamainternmed.2023.0258. PMID: 36972033.
- Teja B, et al. Effectiveness of fludrocortisone plus hydrocortisone versus hydrocortisone alone in septic shock: a systematic review and network meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 2024;209(10):1219-1228. doi:10.1164/rccm.202310-1785OC. PMID: 38271488.
- Lai PC, et al. Do we need to administer fludrocortisone in addition to hydrocortisone in adult patients with septic shock? Crit Care Med. 2024;52(4):e193-e202. doi:10.1097/CCM.0000000000006161. PMID: 38156911.
- Walsham J, et al. Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial. Intensive Care Med. 2024;50(12):2050-2060. doi:10.1007/s00134-024-07616-z. PMID: 39235623.
- Pirracchio R, Annane D, Waschka AK, et al. Patient-level meta-analysis of low-dose hydrocortisone in adults with septic shock. NEJM Evid. 2023;2(6):EVIDoa2300034. doi:10.1056/EVIDoa2300034. PMID: 38320130.
- Hydrocortisone (2023). UpToDate. Accessed August 13, 2023.
- Hydrocortisone sodium succinate (2023). Micromedex. Accessed August 13, 2023.
- Kim G. Prioritizing the patient through a continuum of personalized care: insights from the 2026 Surviving Sepsis Campaign guidelines. Acute Crit Care. 2026;41(2):419-427. doi:10.4266/acc.004550. PMID: 42272214.
- Xu J, Cai H, Zheng X. Effect of methylprednisolone vs hydrocortisone on 30-day mortality in critically ill adults with septic shock: an analysis of the MIMIC-IV database. BMC Infect Dis. 2025;25(1):328. doi:10.1186/s12879-025-10731-x. PMID: 40055601.
- SOLU-CORTEF (hydrocortisone sodium succinate for injection, USP), prescribing information. Pharmacia & Upjohn Company LLC; revised July 2024. DailyMed set ID 65eefd58-b166-4d71-ade6-45c8fdf86922, version 31. Accessed November 11, 2026.
- SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP), prescribing information. Pharmacia & Upjohn Company LLC; revised November 2025. DailyMed set ID 7271310c-7764-4812-aa30-a5e90987c7a9, version 12. Accessed November 11, 2026.
- Fludrocortisone acetate tablets USP, 0.1 mg, prescribing information. Major Pharmaceuticals (manufactured by Novitium Pharma LLC); issued 03/2022. DailyMed set ID 933e28ef-05e8-419e-a786-21eab67f33a2, version 3. Accessed November 11, 2026.
Never Miss a Friday Pearl
Get Pharmacy Pearls in your inbox every Friday
Free weekly clinical pearls written for pharmacists. Practical, evidence-based, and built for bedside use.
Free forever. Unsubscribe anytime. No spam, ever.